Advertisement

Chinese Journal of Integrative Medicine

, Volume 24, Issue 3, pp 227–231 | Cite as

Shenyi Capsule (参一胶囊) plus Chemotherapy versus Chemotherapy for Non-Small Cell Lung Cancer: A Systematic Review of Overlapping Meta-Analyses

  • Xiu-wei Guo
  • Nai-dong Hu
  • Gui-zhi Sun
  • Meng Li
  • Pei-tong Zhang
Evidence-Based Integrative Medicine

Abstract

Objective

To assist decision-makers interpret and choose among conflfl icting meta-analyses, as well as to offer treatment recommendations based on current best evidence by performing a systematic review of overlapping meta-analyses regarding Shenyi Capsule (参一胶囊, SC) plus chemotherapy versus chemotherapy of non-small cell lung cancer (NSCLC).

Methods

A literature search was conducted to select systematic reviews comparing SC plus chemotherapy with chemotherapy for NSCLC. Meta-analyses only composed of randomized controlled trials (RCTs) met the inclusion criteria. Two authors individually estimated the quality of meta-analysis and extracted data. The Jadad decision algorithm was applied to guarantee which meta-analysis provided the best original evidence.

Results

A total of 5 meta-analyses were included. All the studies composed of RCTs or quasi-RCTs and were regarded as level-II evidence. The scores of the Assessment of Multiple Systematic Reviews ranged from 3 to 6 (median 4). A high-quality meta-analysis with more RCTs was chosen, which suggested that SC plus chemotherapy could increase incidence of short-term efficacy, improve the quality of life and survival rate in comparison to chemotherapy. However, there was no statistically significant difference between SC plus chemotherapy and chemotherapy regarding chemotherapy-induced side effect, such as liver and kidney function obstacle, leukopenia, hemoglobin decrement and gastrointestinal adverse reaction.

Conclusions

Based on the best available evidence, treatment effect of SC plus chemotherapy was better than chemotherapy and did not increase side effects. Therefore, SC plus chemotherapy may be superior to chemotherapy for treating NSCLC. However, due to some limitations, SC plus chemotherapy should be cautiously considered, and further high-quality meta-analyses are needed.

Keywords

non-small cell lung cancer Shenyi Capsule Chinese medicine chemotherapy integrative treatment systematic review meta-analysis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen XL, Duan XM, Zhao HF, Teng YL. Treatment strategy for molecular targeted drugs on non-small cell lung cancer. China Pharm (Chin) 2014;25:2080–2082.Google Scholar
  3. 3.
    Zhang X, Ye BD, Chen D, Wu DJ, Zhao YH. Progress on anti-tumor effects and mechanisms of ginsenoside-Rg3. Chin Arch Tradit Chin Med (Chin) 2013;31:328–330.Google Scholar
  4. 4.
    Chen SJ, Li RZ. Clinical observation of Canyi Capsule combined with GP regimen in the treatment of advanced nonsmall cell lung cancer. Contemp Med (Chin) 2012;18:1–2.Google Scholar
  5. 5.
    Li CY, Li QY, Xu J. Clinical observation of Canyi Capsule combined with GP regimen in the treatment of advanced non-small cell lung cancer. Cancer Res Prev Treat (Chin) 2012;39:1125–1127.Google Scholar
  6. 6.
    Li HB, Liu WL, Zhang QY, Kang XM, Zhao WH. The efficacy analysis of low-dose cyclophosphamide combined with ginsenoside Rg3 on advanced non small cell lung cancer. Pract Oncol J (Chin) 2006;20:18–20.Google Scholar
  7. 7.
    Liu H, Hou W, Wang H, Lin HS. Clinical research on Shenyi Capsule combined with gefitinib for advanved non-small cell lung cancer: a report of 50 cases. J Tradit Chin Med (Chin) 2012;53:933–935, 966.Google Scholar
  8. 8.
    Liu SQ, Sun LX, Ban LY, Zhou T. Ginsenoside Rg3 capsules combined NP regimen in the treatment of advanced non-small cell lung cancer. Chin Clin Oncol (Chin) 2007;12:847–849.Google Scholar
  9. 9.
    Liu XG, Yang HB, Li L, Xing LN. Effect observation of Shenyi Capsule combined chemotherapy for treatment of advanced non-small cell lung cancer. Jilin Med J (Chin) 2009;30:2319–2320.Google Scholar
  10. 10.
    Liu Y, Liu S, Xu CA. Clinical observation of chemotherapy plus Shenyi Capsule for treatment of advanced non-small cell lung cancer. Shanxi Med J (Chin) 2007;36:554–556.Google Scholar
  11. 11.
    Qi CW, Zhang HT. Ginsenoside Rg3 combined GP regimen in the treatment of advanced non-small cell lung cancer. J Clin Med Pract (Chin) 2011;15:121–122.Google Scholar
  12. 12.
    Shao HL. Clinical observation on Shenyi Capsule combined with docetaxel for elderly patients with advanced non-small cell lung cancer. Shanxi Med J (Chin) 2013;42:738–740.Google Scholar
  13. 13.
    Shi MQ, Feng JF, Pan LX, Zhou ZF. Clinical observation of treating non-small-cell lung cancer by chemotherapy and Shenyi Capsule. Chin Clin Oncol (Chin) 2006;11:193–194, 197.Google Scholar
  14. 14.
    Sun Yan, Lin HS, Zhu YZ, Feng JF, Chen ZT, Li GS, et al. A randomized, prospective, multi-centre clinical trial of NP regimen (vinorelbine + cisplatin) plus Gensing Rg3 in the treatment of advanced non-small cell lung cancer patients. Chin J Lung Cancer (Chin) 2006;9:254–258.Google Scholar
  15. 15.
    Wang XQ, Zhang M. Effect observation of Shenyi Capsule combined with radiation and chemotherapy treatment for elderly advanced non-small cell lung cancer. J Pract Med (Chin) 2013;29:1885–1886.Google Scholar
  16. 16.
    Xu S, Zhao YX, Long D. Effect of Canyi Capsule combined with single chemotherapy drug in maintenance treatment for patients with advanced non-small cell lung cancer. J Guangzhou Univ Tradit Chin Med (Chin) 2013;3:337–340.Google Scholar
  17. 17.
    Qin SK, Chen YX, Wang L, Liu XF, He ZM, Wang JS. Clinial study on qi deficiency patients with non-small cell lung cancer (NSCLC) treated by Shenyi Capsule. Chin Clin Oncol (Chin) 2001;04:327–329,331.Google Scholar
  18. 18.
    Lin HS, Piao BK, Li SQ. Phase II clinical trial report of treating lung cancer with Shenyi Capsule. Chin J Clin Oncol (Chin) 2002;4:276–279.Google Scholar
  19. 19.
    Chen WM, Yao Y, Shi ZZ. Observation of curative effect of combined 20(r)-ginsenoside Rg3 with chemotherapy with non small cell lung cancer. Mil Med J South China (Chin) 2005;1:4–6.Google Scholar
  20. 20.
    Wang Y, Liu JL, Zhao HL, Yang MP, Li X, Liu L. Curative effect observation of ginseng saponins Rg3 capsule combined With chemotherapy for treatment of advanced non-small cell lung cancer. Pract Oncol J (Chin) 2011;25:33–35.Google Scholar
  21. 21.
    Du LX. clinical observation of Shenyi Capsule auxiliary treatment of advanced non-small cell lung cancer. Neimongol J Tradit Chin Med (Chin) 2014;33(34):7.Google Scholar
  22. 22.
    Pang M. Correlation studies of the near future curative effect of Shenyi Capsule adjuvant chemotherapy treatment on advanced non-small cell lung cancer and the serum levels changes of VEGF/bFGF [dissertation]. Jinan: Jinan University; 2012:47.Google Scholar
  23. 23.
    Tu H. Curative effect observation of serum vascular endothelial growth factor of ginseng saponins Rg3 plus chemotherapy for treatment of advanced non-small cell lung cancer patients [dissertation]. Fuzhou: Fujian University Traditional Chinese Medicine; 2008:30.Google Scholar
  24. 24.
    Zhu JP, Yu LK, Hao KK, Zhang Y, Sun ZK. Treat non-small cell lung cancer with Shenyi Capsule plus chemotherapy: a systematic review. Liaoning J Tradit Chin Med (Chin) 2009;9:1444–1447.Google Scholar
  25. 25.
    Hu SS, Zhou LK, BA Y, Li HL, Zhu CH. A meta-analysis of ginsenoside Rg3 for non-small cell lung cancer. Clin Oncol Cancer Res 2011;8:175–180.CrossRefGoogle Scholar
  26. 26.
    Xia HX, Jiao LB, Hu W. A meta-analysis of therapeutic efficacy of Shenyi Capsule combined with chemotherapy for advanced non-small cell lung cancer. China Pharm (Chin) 2014;20:1887–1891.Google Scholar
  27. 27.
    Xu LN, Zhang NZ. Clinical effect and safety meta-analysis of adjuvant chemotherapy of ginseng 1 capsule for nonsmall cell lung cancer. Yunnan J Tradit Chin Med Mater Med (Chin) 2015;7:14–16.Google Scholar
  28. 28.
    Fang SS, Ge W, Song J, Luo W, Chen C. System evaluation of the effectiveness and safety of Rg3 combined with chemotherapy for advanced non-small cell lung cancer. China Med Herald (Chin) 2015;35:87–92.Google Scholar
  29. 29.
    Mascarenhas R, Cvetanovich GL, Sayegh ET, Verma NN, Cole BJ, Bush Joseph C, et al. Does double-bundle anterior cruciate ligament reconstruction improve postoperative knee stability compared with single-bundle techniques? A systematic review of overlapping meta-analyses. Arthroscopy 2015;31:1185–1196.PubMedGoogle Scholar
  30. 30.
    Zhao JG, Wang J, Wang C, Kan SL. Intramedullary nail versus plate fixation for humeral shaft fractures: a systematic review of overlapping meta-analyses. Medicine (Baltimore) 2015;94:e599.CrossRefGoogle Scholar
  31. 31.
    Mascarenhas R, Chalmers PN, Sayegh ET, Bhandari M, Verma NN, Cole BJ, et al. Is double-row rotator cuff repair clinically superior to single-row rotator cuff repair: a systematic review of overlapping meta-analyses. Arthroscopy 2014;30:1156–1165.CrossRefPubMedGoogle Scholar
  32. 32.
    Zhao JG, Wang J, Long L. Surgical versus conservative treatments for displaced midshaft clavicular fractures: a systematic review of overlapping meta-analyses. Medicine (Baltimore) 2015;94:e1057.CrossRefGoogle Scholar
  33. 33.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.CrossRefGoogle Scholar
  34. 34.
    Wright JG, Swiontkowski MF, Heckman JD. Introducing levels of evidence to the journal. J Bone Joint Surg Am 2003;85:1–3.CrossRefPubMedGoogle Scholar
  35. 35.
    Shea BJ, Grimshaw JM, Wells GA, Boer M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;7:1–7.CrossRefGoogle Scholar
  36. 36.
    Jadad AR, Cook DJ, Browman GP. A guide to interpreting discordant systematic reviews. CMAJ 1997;156:1411–1416.PubMedPubMedCentralGoogle Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2017

Authors and Affiliations

  • Xiu-wei Guo
    • 1
  • Nai-dong Hu
    • 2
  • Gui-zhi Sun
    • 1
  • Meng Li
    • 1
  • Pei-tong Zhang
    • 1
  1. 1.Department of Oncology, Guang’anmen HospitalChina Academy of Chinese Medical SciencesBeijingChina
  2. 2.Department of Oncology, The East Campus of Dongzhimen HospitalBeijing University of Chinese MedicineBeijingChina

Personalised recommendations